

मिसिलस.- 8(31)/2016/डी.पी./एनपीपीए- डीवी-II

F. No. 8(31)/2016/DP/NPPA-Div. II

कार्यवाहीस. : 163/31/2016/F
Proceeding No : 163/31/2016/F

Minutes of the 163rd and 31st meeting of Authority under DPCO, 2013 held on 18.5.2016 at 11.00 AM.

- I. 1. The 163rd overall meeting of the Authority, which is the 31st under the DPCO, 2013 was held on 18th May, 2016 at 11.00 AM under the Chairmanship of Shri Bhupendra Singh, Chairman, NPPA. The following members of the NPPA were present:-

- (i) Dr. Sharmila Mary Joseph K, Member Secretary, NPPA.
- (ii) Dr. K.L. Prasad, Member (Ex-Officio), Adviser, Economic Division, Deptt. of Economic Affairs.
- (iii) Shri Devendra Kumar, Adviser (Cost), Deptt. of Expenditure, Ministry of Finance.
- (iv) Shri Sanjeev Kumar, Assistant Drug Controller, Deptt. of Health & Family Welfare (representing DCGI).

1.1 The following officers of NPPA also attended the meeting and assisted the Authority in its deliberations:-

- (i) Shri Kalyan Nag, Adviser (Cost)
- (ii) Smt. Roshni Sohni, Director (M&E/Admn.)
- (iii) Shri A.K. Khurana, Director (Pricing & Admn.)
- (iv) Shri A.P.S. Sawhney, Director (Overcharging)
- (v) Shri T.R. Satish Chandran, Asstt. Director (Pricing)
- (vi) Shri Baljit Singh, Asstt. Director (Pricing)
- (vii) Shri Suneel Chopra, Pr. Legal Consultant

1.2 Chairman, NPPA welcomed all the members present in the meeting.

II. Agenda Items

1. Agenda Item no. 1: Confirmation of Minutes of the 30th Meeting held on 09.5.2016.

Since no comments were received on the minutes of 162nd and the 30th Meeting under DPCO, 2013, the Authority confirmed the minutes of the meeting.

2. Agenda Item no. 2: Action Taken Report

Noted.

3. Agenda Item no. 3: Fixation of Ceiling Prices of Scheduled formulations in the revised Schedule-I of DPCO, 2013 (NLEM, 2015).

3.1 The Authority discussed in detail the data on 25 formulations and approved the ceiling prices in respect of all the following 25 formulations.

Sl. No.	NLEM Number	Formulation	Strength	Unit for ceiling price	Ceiling Price (Rs.)
Common Formulations					
1	2.4.2	Hydroxychloroquine	200 mg Tablet	Per Tablet	5.50
2	2.4.5	Sulfasalazine	500 mg Tablet	Per Tablet	3.70
3	3.4	Dexamethasone	0.5mg Tab	Per Tablet	0.18
4	3.7	Prednisolone	5 mg Tablet	Per Tablet	0.52
5	3.7	Prednisolone	10 mg Tablet	Per Tablet	0.90
6	5.8	Phenytoin	100 mg Tablet	Per Tablet	1.27
7	6.2.1.1	Amoxicillin	500 mg Capsule	Per Capsule	5.70
8	6.2.1.2	Amoxicillin (A) + Clavulanic Acid (B)	500 mg (A) + 125 mg (B) Tablet	Per Tablet	16.14
9	6.2.1.2	Amoxicillin (A) + Clavulanic Acid (B)	1gm (A)+200mg (B) Powder for injection	Each Pack	113.91
10	6.2.1.8	Cefixime	200 mg Tablet	Per Tablet	8.48
11	6.2.2.7	Metronidazole	400 mg Tablet	Per Tablet	0.75
12	9.1	Levodopa (A) +Carbidopa (B)	100mg (A)+25mg (B) Tablet	Per Tablet	2.10
13	9.1	Levodopa (A) +Carbidopa (B)	100mg (A)+10 mg (B) Tablet	Per Tablet	1.44
14	10.1.4	Folic Acid	5 mg Tablet	Per Tablet	1.28
15	12.2.2	Amiodarone	200 mg Tablet	Per Tablet	10.51
16	12.3.8	Sodium Nitroprusside	10 mg/ml Injection	Per ML	23.95
17	12.4.1	Digoxin	0.25mg Tab	Per Tablet	1.11
18	20.1.1	Omeprazole	20mg Capsule	Per Capsule	2.31
19	20.6.1	Oral Rehydration Salts	-	Per GM	0.71
20	21.4.1.2	Insulin (Soluble)	40 IU/ml injection	Per ML	13.34
21	21.4.1.3	Intermediate Acting (NPH) Insulin	40 IU/ml injection	Per ML	13.34
22	21.4.1.5	Premix Insulin 30:70 Injection (Regular:NPH)	40 IU /ml Injection	Per ML	13.34
23	21.7.1	Carbimazole	10mg Tab	Per Tablet	3.42
24	26.1.3	Mifepristone	200mg Tablet	Per Tablet	298.49
Newly Added Formulations					
25	20.6.1	Oral Rehydration Salts	-	Per ML	0.12648

3.2 Further, it was discussed and decided that any earlier order issued regarding retail price(s) or ceiling price(s) for such formulations, if any, will be superseded by the new price order(s) by notification.

4. Agenda Item no. 4: Fixation of retail price in respect of new drugs.

The Authority discussed the following 4 cases of retail price fixation of new drugs falling under the purview of para 2(u) of DPCO, 2013 and approved the retail prices of the following under para 5 of the DPCO 2013, as under:

S. No.	Company name/Product name	Approved Price (Rs.)
4(i)	M/s Pharma Force Lab. (Manufacturer) and M/s Mankind Pharma Ltd. (Marketing company) – Clobetasol Propionate 0.05% w/w, Clotrimazole 1% w/w and Neomycin Sulphate 0.50% w/w – (Terbinaforce-Lite Cream).	3.32/gm
4(ii)	M/s Natco Pharma Ltd. (Manufacturer) and M/s Fresenius Kabi Pvt. Ltd. (Marketing company) – Doxorubicin HCl 2mg – (Pegylated Liposomal Doxorubicin Injection).	754.26/ml
4(iii)	M/s Embiotic Lab. Pvt. Ltd. (Manufacturer as well as Marketing company) – Paracetamol 325mg and Etoricoxib 60mg – (Etoricoxib & Paracetamol Tablet).	5.36/tablet
4(iv)	M/s Kilitch Healthcare LLP (Manufacturer) and M/s Cadila Healthcare Ltd. (Marketing company) – Travoprost – 0.0004% w/v and Timolol Maleate eq. to Timolol – 0.5% w/v – (Travoprost & Timolol Maleate ophthalmic solution).	131.00/ml

5.1 Agenda Item no. 5 (a): Representation for Price revision of 'Abacavir 600mg + Lamivudine 300mg' tablet notified vide S.O No.1253 (E) dated 29.03.2016 (S.No.42).

The Authority discussed in detail and approved the revised ceiling price of Rs. 84.55/tablet.


5.2 Agenda Item no. 5 (b): Representation for Price revision of 'Cefotaxime 1gm' powder for injection notified vide S.O No.1405 (E) dated 12.4.2016 (S.No.4).

The Authority discussed in detail and approved the revised ceiling price of Rs. 31.85/pack.

6. Agenda Item no. 6: Discontinuation of Scheduled formulations under para 21(2) of DPCO, 2013.

6.1 Noted.

7. The meeting ended with vote of thanks to the chair.


(Dr. Sharmila Mary Joseph K)
Member Secretary